Match!
Layal Sayegh
Emory University
CancerOncologyChemotherapyPancreatic cancerMedicine
3Publications
0Citations
What is this?
Publications 4
Newest
#1Matthew R. Farren (Emory University)H-Index: 2
#1Matthew R. FarrenH-Index: 5
Last. Gregory B. LesinskiH-Index: 29
view all 15 authors...
Pancreatic ductal adenocarcinoma (PDAC) has dismal 5-year survival (<9%). We hypothesize that exposure of tumors to conventional therapies may preferentially modulate immune biomarkers in the tumor microenvironment in PDAC. PDAC patients who underwent upfront surgical resection or who received neoadjuvant FOLFIRINOX with or without neoadjuvant radiotherapy followed by surgical resection were selected for study. Total expression of immunologically relevant transcripts and spatially resolved expre...
Source
#1Walid L. ShaibH-Index: 12
Last. Bassel F. El-RayesH-Index: 29
view all 14 authors...
ObjectivesPancreatic cancer (PDAC) with localized stage includes resectable (RPC), borderline resectable (BRPC), or locally advanced unresectable (LAPC). Standard of care for RPC is adjuvant chemotherapy. There are no prospective randomized trials for best treatment of BRPC and LAPC. We evaluate the
Source
#1Matthew R. Farren (Emory University)H-Index: 2
#2Walid L. Shaib (Emory University)H-Index: 12
Last. Gregory B. Lesinski (Emory University)H-Index: 29
view all 11 authors...
Pancreatic ductal adenocarcinoma (PDAC) has dismal five-year survival ( Citation Format: Matthew R. Farren, Walid Shaib, Mohammad Zaidi, Layal Sayegh, David Kooby, Shishir Maithel, Alyssa Krasinskas, Olatunji Alese, Juan Sarmiento, Bassel El-Rayes, Gregory B. Lesinski. Comparison of neoadjuvant FOLFIRINOX alone vs FOLFIRINOX + stereotactic body radiation as immune-modulators of the pancreatic adenocarcinoma microenvironment [abstract]. In: Proceedings of the American Association for Cancer Resea...
Source
#1Walid L. ShaibH-Index: 12
#2Layal Sayegh (Emory University)
Last. Bassel F. El-RayesH-Index: 29
view all 14 authors...
406Background: Survival of resectable pancreas cancer (RPC) treated with resection and adjuvant therapy is 22-28 months (mo). Locally advanced unresectable pancreatic cancer (LAPC) treated with combination chemotherapy have a median survival of 24 mo. The objective of this project is to evaluate the effect of neoadjuvant treatment on survival outcome of localized PC. Methods: Charts of localized PC patients treated at Emory University from 2009 to 2016 were reviewed. Information on demographics,...
Source
1